about
Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve OutcomesCystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.Association between Serum Fibroblast Growth Factor 21 and Coronary Artery Disease in Patients with Type 2 Diabetes.Enhanced expression of two discrete isoforms of matrix metalloproteinase-2 in experimental and human diabetic nephropathy.Adiposity in the Relationship between Serum Vitamin D Level and Insulin Resistance in Middle-Aged and Elderly Korean Adults: The Korea National Health and Nutrition Examination Survey 2008Current status of diabetic peripheral neuropathy in Korea: report of a hospital-based study of type 2 diabetic patients in Korea by the diabetic neuropathy study group of the korean diabetes association.Changes in Urinary Angiotensinogen Associated with Deterioration of Kidney Function in Patients with Type 2 Diabetes Mellitus.Arterial Stiffness Is More Associated with Albuminuria than Decreased Glomerular Filtration Rate in Patients with Type 2 Diabetes Mellitus: The REBOUND Study.Ectopic ACTH syndrome caused by pulmonary carcinoid tumor mimicking long-standing sclerosing hemangioma.Urine clusterin/apolipoprotein J is linked to tubular damage and renal outcomes in patients with type 2 diabetes mellitus.Prevalence of BRAFV600E Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAFV600E Prevalent Area.Combined Aerobic and Resistance Exercise Training Reduces Circulating Apolipoprotein J Levels and Improves Insulin Resistance in Postmenopausal Diabetic WomenEfficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled StudyApolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivityAuthor Correction: Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivityDifferential Urinary Proteome Analysis for Predicting Prognosis in Type 2 Diabetes Patients with and without Renal Dysfunction
P50
Q26744419-27CA40F0-CC64-4FA2-BE7B-0A2816FE395FQ34539983-D6C8A57B-D954-42F2-8483-5F68383D2406Q35553693-9EF435E1-9AB7-4153-9F73-2CA73DA2847BQ36274282-9C233651-DDF4-4A9C-A1E6-286482E1EDCEQ37264471-DEB547DE-2E86-4356-9079-860E1FFB72C1Q37630964-AECF13E5-F2AA-4DD1-86B9-B63D545C93C8Q37740463-1FD43F20-D4E1-466D-8381-D56AF0C391CEQ41689200-7E53252F-4E28-4C3C-961E-5399E1B9A7A2Q42426663-97709FC1-B6A2-47E2-8BF3-53B6F76007B7Q48244006-5435AF93-5FE4-45F7-A5F1-18F105B4B44BQ55394993-391D0EB2-B8DF-4893-A411-86816EEE0F06Q89878216-DC42F193-20EE-41F4-BD6B-FE9381A6F2ADQ92141978-B4EF726F-76E4-4CD9-A982-EE816D230BA7Q93216603-7AF05B6D-32A7-4959-80DF-3BD1E529C45EQ94554117-9E87DC95-1684-4776-A15A-DC3C0DE84A9DQ96429651-DCDE496E-A09A-4799-B91B-9A0E748ED274
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sang Soo Kim
@ast
Sang Soo Kim
@en
Sang Soo Kim
@es
Sang Soo Kim
@nl
Sang Soo Kim
@sl
type
label
Sang Soo Kim
@ast
Sang Soo Kim
@en
Sang Soo Kim
@es
Sang Soo Kim
@nl
Sang Soo Kim
@sl
prefLabel
Sang Soo Kim
@ast
Sang Soo Kim
@en
Sang Soo Kim
@es
Sang Soo Kim
@nl
Sang Soo Kim
@sl
P106
P1153
57022618600
P31
P496
0000-0002-9687-8357